NCT05160272View on ClinicalTrials.gov

Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 7, 2022

Primary Completion Date

December 17, 2024

Study Completion Date

December 17, 2024

Conditions
Type2 Diabetes
Interventions
DRUG

AP-325

Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.

DRUG

Placebo matching AP-325

Measurement of the effect of AP-325 50mg/d compared to matching placebo after 4-week treatment.

Trial Locations (1)

40225

German Diabetes Center, Düsseldorf

Sponsors
All Listed Sponsors
collaborator

Algiax Pharmaceuticals GmbH

INDUSTRY

lead

The Deutsche Diabetes Forschungsgesellschaft e.V.

OTHER

NCT05160272 - Effects of GABAA Receptor Modulation by AP-325 on Insulin Secretion in Patients with Type 2 Diabetes | Biotech Hunter | Biotech Hunter